Pesquisar
Connect Biopharma Holdings Ltd
CNTBAdicionar à lista de desejos
1.070USD
-0.145-11.93%
Fechamento 09-23 16:00（ET）
59.62MValor de mercado
PerdaP/L TTM
Pré-mercado 08:14 (ET)1.095USD+0.025+2.34%
Pré-mercado 08:14 (ET)Sobre o Connect Biopharma Holdings Ltd Empresa
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Connect Biopharma Holdings Ltd Perfil
Código da empresaCNTB
Nome da EmpresaConnect Biopharma Holdings Ltd
Data de listagemMar 19, 2021
CEOQuart (Barry D)
Número de funcionários62
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 19
Endereço3580 Carmel Mountain Road, Suite 200
CidadeSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92130
Telefone18587271040
Sitehttps://www.connectbiopharm.com
Código da empresaCNTB
Data de listagemMar 19, 2021
CEOQuart (Barry D)
Executivos da empresa Connect Biopharma Holdings Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Ms. Lisa Peraza, CPA
Ms. Lisa Peraza, CPA
Vice President - Finance
Vice President - Finance
45.19K
--
Ms. Lisa Peraza, CPA
Ms. Lisa Peraza, CPA
Vice President - Finance
Vice President - Finance
45.19K
--
Ms. Lisa Peraza, CPA
Ms. Lisa Peraza, CPA
Vice President - Finance
Vice President - Finance
45.19K
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
11.78K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Perguntas frequentes
Quem são os cinco principais acionistas de Connect Biopharma Holdings Ltd?
Os cinco principais acionistas de Connect Biopharma Holdings Ltd são: Dr. Barry D. Quart, Pharm.D.
Quantas instituições possuem ações da Connect Biopharma Holdings Ltd (CNTB)?
Em 2026Q1, 51 instituições possuíam ações da Connect Biopharma Holdings Ltd, com valor de mercado aproximado de 29.94M, representando 52.97% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 8109973.00.